Keverprazan is a potassium-competitive acid blocker (P-CAB) and active pharmaceutical ingredient developed for the treatment of acid-related gastrointestinal disorders. It suppresses gastric acid secretion by directly and reversibly inhibiting the gastric H⁺/K⁺-ATPase proton pump in gastric parietal cells.
Unlike conventional proton pump inhibitors, Keverprazan does not require acid activation. Its potassium-competitive mechanism enables direct inhibition of the proton pump and provides potent suppression of gastric acid secretion.
Keverprazan is a synthetic small-molecule gastric acid secretion inhibitor. It is identified by CAS Number 2413064-02-3 and has the molecular formula C21H23N5O2S with a molecular weight of approximately 409.51 g/mol.
Keverprazan is supplied as a pharmaceutical-grade active ingredient for formulation and pharmaceutical manufacturing applications.
Keverprazan selectively and reversibly inhibits the H⁺/K⁺-ATPase proton pump by competing with potassium ions at the proton pump. This inhibits the final step of gastric acid secretion by gastric parietal cells.
Because its activity is not dependent on acid activation, Keverprazan can provide rapid and sustained suppression of gastric acid secretion.
Keverprazan has been developed for acid-related gastrointestinal disorders, including gastroesophageal reflux disease (GERD) and other conditions associated with excessive gastric acid secretion. It has also been investigated for use in the treatment of peptic ulcer disease and other acid-related disorders.
Keverprazan API can be evaluated using validated analytical procedures for identity, assay, related substances, water content, residual solvents and elemental impurities. HPLC and appropriate spectroscopic techniques may be used for identification and purity assessment.
Acceptance criteria should be based on the applicable approved drug-substance specification and Certificate of Analysis.
Keverprazan should be stored in a tightly closed pharmaceutical-grade container under controlled storage conditions. The material should be protected from excessive heat, moisture, direct light and contamination. Specific storage requirements should follow the applicable manufacturer's specification.
Keverprazan API may be supplied for qualified pharmaceutical manufacturing, formulation development, research and analytical applications. Product specifications, Certificate of Analysis, packaging details and regulatory documentation should be confirmed according to the intended application.
Keverprazan API is available for pharmaceutical development and manufacturing requirements subject to applicable quality and regulatory requirements. Customers can request product specifications, analytical documentation, Certificate of Analysis, packaging information and commercial details for their specific requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 4.0 – 7.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |